SEK 242.0
(0.05%)
Year | Eps | Eps Growth |
---|---|---|
2023 | 0.12 EUR | 48.15% |
2022 | 0.08 EUR | -88.26% |
2021 | 0.69 EUR | 283.33% |
2020 | 0.18 EUR | 5.88% |
2019 | 0.17 EUR | -5.56% |
2018 | 0.18 EUR | 12.5% |
2017 | 0.16 EUR | 247.83% |
2016 | 0.05 EUR | -18.15% |
2015 | 0.06 EUR | 73.99% |
2014 | 0.03 EUR | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | 0.04 EUR | -47.23% |
2024 Q2 | 0.04 EUR | 2.44% |
2023 Q3 | -0.01 EUR | -118.92% |
2023 Q1 | 0.01 EUR | 10.16% |
2023 Q4 | 0.08 EUR | 1210.0% |
2023 Q2 | 0.04 EUR | 162.41% |
2023 FY | - EUR | 48.15% |
2022 Q3 | -0.02 EUR | -216.92% |
2022 FY | - EUR | -88.26% |
2022 Q4 | 0.01 EUR | 156.14% |
2022 Q2 | 0.02 EUR | -75.69% |
2022 Q1 | 0.08 EUR | -57.79% |
2021 FY | - EUR | 283.33% |
2021 Q2 | 0.20 EUR | 17.65% |
2021 Q3 | 0.12 EUR | -40.0% |
2021 Q4 | 0.19 EUR | 58.33% |
2021 Q1 | 0.17 EUR | 41.67% |
2020 Q3 | 0.11 EUR | 297.84% |
2020 Q4 | 0.12 EUR | 9.09% |
2020 FY | - EUR | 5.88% |
2020 Q1 | -0.01 EUR | -112.32% |
2020 Q2 | -0.06 EUR | -826.67% |
2019 FY | - EUR | -5.56% |
2019 Q4 | 0.05 EUR | 13.26% |
2019 Q3 | 0.04 EUR | 38.71% |
2019 Q2 | 0.03 EUR | -32.61% |
2019 Q1 | 0.05 EUR | 80.39% |
2018 Q3 | 0.04 EUR | 15.38% |
2018 Q4 | 0.03 EUR | -43.33% |
2018 Q1 | 0.06 EUR | -11.11% |
2018 FY | - EUR | 12.5% |
2018 Q2 | 0.04 EUR | -35.0% |
2017 Q1 | 0.04 EUR | 455.56% |
2017 Q3 | 0.03 EUR | 87.5% |
2017 Q2 | 0.02 EUR | -60.0% |
2017 FY | - EUR | 247.83% |
2017 Q4 | 0.07 EUR | 125.0% |
2016 Q1 | 0.02 EUR | 0.0% |
2016 Q3 | 0.03 EUR | 300.0% |
2016 Q2 | -0.02 EUR | -194.94% |
2016 Q4 | 0.01 EUR | -76.0% |
2016 FY | - EUR | -18.15% |
2015 FY | - EUR | 73.99% |
2014 FY | - EUR | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Xvivo Perfusion AB (publ) | 3.07 SEK | 96.091% |